Evaluation of fecal microRNA stability in healthy cats by Lyngby, Janne G. et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Evaluation of fecal microRNA stability in healthy cats
Lyngby, Janne G.; Kristensen, Annemarie T.; Fredholm, Merete; Nielsen, Lise N.; Cirera,
Susanna
Published in:
Veterinary Clinical Pathology
DOI:
10.1111/vcp.12757
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Lyngby, J. G., Kristensen, A. T., Fredholm, M., Nielsen, L. N., & Cirera, S. (2019). Evaluation of fecal microRNA
stability in healthy cats. Veterinary Clinical Pathology, 48(3), 455-460. https://doi.org/10.1111/vcp.12757
Download date: 03. Feb. 2020
Vet Clin Pathol. 2019;48:455–460.	 	 	 | 	455wileyonlinelibrary.com/journal/vcp
1  | INTRODUC TION
Gastrointestinal (GI) cancer in cats accounts for around 14% of fe‐
line malignancies,1 and with advances in veterinary diagnostics and 
willingness to diagnose and treat feline patients, the importance of 
reaching a diagnosis to initiate a correct treatment is as important as 
ever.2 Lymphoma is the most common GI cancer in cats followed by 
adenocarcinoma and mast cell tumors.2 Of the lymphomas, approx‐
imately 75% are small cell lymphoma.3 The preferred treatment and 
prognosis vary significantly with the different cancer types, hence 
reaching a diagnosis will determine the best therapeutic option for 
a patient.
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Abstract
Background: Gastrointestinal (GI) cancer accounts for 14% of feline malignancies. 
There is a great need for reliable noninvasive diagnostic biomarkers to reach a timely 
diagnosis	 and	 initiate	 treatment.	 Fecal	microRNAs	 (miRNAs)	 could	 be	 such	 a	 bio‐
marker and have shown great potential in colorectal screening in people but have yet 
to be investigated in cats.
Objectives: We	aimed	to	evaluate	the	presence	and	stability	of	feline	fecal	miRNA	
under	 different	 storage	 conditions	 (room	 temperature	 [RT],	 4,	 and	 −20°C)	 and	 to	
evaluate	the	expression	levels	of	specific	fecal	miRNAs	collected	on	three	separate	
days (days 1, 4, and 7) in healthy cats.
Methods: Healthy	cats	were	prospectively	recruited.	Fecal	samples	were	collected,	
aliquoted,	and	stored	for	24	hours	at	RT	and	then	transferred	to	−20°C,	stored	for	
24	hours	at	4°C	and	then	transferred	to	−20°C,	or	were	immediately	placed	at	−20°C	
on	day	1	or	at	−20°C	on	days	4	and	7	postcollection.	Expression	of	22	miRNAs	was	
investigated using quantitative real‐time PCR.
Results: Ten	miRNA	assays	worked	well,	and	one,	let‐7b,	was	used	for	normalization.	No	
differences	in	miRNA	expression	were	seen	between	the	three	storage	temperatures	for	
the	nine	miRNAs	investigated.	Only	miR‐26a	showed	a	significant	increase	in	expression	
between	samples	of	days	1	and	7.	The	rest	of	the	miRNAs	levels	were	stable	over	time.
Conclusions: Fecal	miRNA	can	be	 isolated	 from	healthy	 cats.	 The	expression	was	
stable	at	different	temperatures	and	for	most	of	the	miRNAs	over	time.	Prospective	
studies	evaluating	fecal	miRNA	as	biomarkers	in	cats	with	GI	neoplasia	are	warranted.
K E Y W O R D S
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Unfortunately,	the	clinical	signs	of	GI	cancer	are	nonspecific	and	not	
significantly different from those of other chronic enteropathies. This 
includes weight loss, vomiting, diarrhea and/or hyporexia/anorexia, 
which makes it difficult to differentiate one disease from another.4,5 
To rule out extraintestinal disease and reach a diagnosis, a systematic 
work‐up is required. This can include a hemogram, serum biochemical 
panel, basal cortisol/adrenocorticotropic hormone stimulation testing, 
pancreatic lipase immunoreactivity (PLI), trypsin‐like immunoreactivity 
(TLI),	cobalamin,	and	folate.	Moreover,	urine	and	fecal	testing,	abdom‐
inal ultrasound, and GI biopsies with histopathologic evaluations are 
used to differentiate between various chronic enteropathies and pro‐
vide a correct diagnosis.4 This can be costly and potentially invasive, re‐
sulting in some clients and veterinarians electing to initiate therapeutic 
trials	or	euthanize	a	patient	without	a	firm	diagnosis.	Even	if	a	diagnosis	
is reached, the time from initial primary complaint to diagnosis is often 
prolonged, thereby delaying correct treatments and potentially result‐
ing in disease progression and decreased survival times. Thus, fast, re‐
liable, and noninvasive diagnostic tests to differentiate GI cancer from 
other chronic enteropathies in cats is needed.
MicroRNAs	(miRNAs)	are	small	noncoding	RNAs	that	have	import‐
ant roles in gene regulation. They exert their function at the post‐tran‐
scriptional	level	by	binding	to	the	complementary	mRNA	strands	and	
thereby	 inhibiting	 translation	 and/or	 triggering	 	mRNA	degradation.	
MicroRNA	regulation	is	essential	for	many	processes	involved	in	cell	
division and maturation in many species and both health and disease.6 
Recently	fecal	miRNA	has	been	investigated	as	a	noninvasive	screen‐
ing test for colorectal cancer (CRC) in humans.7 Our group has vali‐
dated	an	assay	for	extraction	of	fecal	miRNA	from	dogs	and	assessed	
its stability; however, no similar information exists in cats.8
Our objective was to evaluate the presence and stability of fecal 
miRNA	under	different	storage	conditions	(room	temperature	[RT],	
4,	and	−20°C)	and	to	evaluate	the	expression	levels	of	specific	fecal	
miRNAs	on	three	separate	days	(days	1,	4,	and	7)	in	healthy	cats.	We	
hypothesized	that	reliable,	stable,	and	specific	fecal	miRNA	expres‐
sion could be established in healthy cats.
2  | MATERIAL S AND METHODS
2.1 | Patient recruitment and screening
This study was approved by the ethics committee of the Department 
of	Veterinary	Clinical	Sciences,	University	of	Copenhagen	(#2017‐9)	
with informed client consent. The study was conducted during the 
summer of 2017.
Sixteen	healthy	adult	privately	owned	cats	were	prospectively	
recruited for this research project. The cats were fed a commercially 
available wet and/or dry cat food, and no intervention was made to 
the diets on behalf of the study.
Each cat was fasted prior to examination, and a full physical ex‐
amination was performed by one of the authors (JGL). Blood was 
collected for routine hematology, serum biochemistry panel, total 
thyroxin (tT4), and urine and feces were collected for a urinalysis and 
fecal flotation, respectively. The urine sample was collected from 
clean litterboxes with nonabsorbent litter following ethics approval. 
Cats were excluded if they weighed less than 2.5 kg, were fed a raw 
food diet, were found to have GI abnormalities on physical examina‐
tion, had received any medications including anti‐inflammatory or 
immunosuppressive drugs within 6 weeks of the study start, or had 
been dewormed within a month of the study start.
2.2 | Fecal collection, transportation, and storage
As	part	of	the	study,	clients	were	provided	an	at‐home	fecal	collec‐
tion protocol that included a written manual that was explained to 
the client and all materials needed for fecal collection.
To	assess	miRNA	stability	and	compare	the	effect	of	different	stor‐
age temperatures, feces were collected on three different days—days 
1,	4,	and	7.	Samples	were	collected	from	the	 litterbox	as	soon	after	
defecation	as	possible	and	within	one	hour.	Approximately	one	gram	
of each fecal samples was aliquoted into 2.0‐mL cryotubes in dupli‐
cate	for	each	storage	condition.	See	Figure	1	for	a	schematic	presenta‐
tion of the fecal collection and storage protocol. On day 1, two tubes 
were	stored	at	RT	(approximately	22°C)	for	24	hours	and	then	moved	
to	–20°C,	 two	cryotubes	were	stored	at	4°C	for	24	hours	and	then	
moved	to	−20°C,	and	two	cryotubes	were	stored	directly	at	−20°C	(see	
Figure	1).	To	evaluate	intra‐cat	miRNA	variation	among	the	different	
collection	days,	two	cryotubes	were	stored	directly	at	−20°C	on	three	
different	days	(days	1,	4,	and	7).	The	samples	were	stored	at	−20°C	in	
different	household	freezers	to	represent	at‐home	collection.	Within	
F I G U R E  1   The protocol for fecal collection and storage from 
each feline patient. On day 1, the fecal sample was aliquoted and 
stored	in	duplicate	at	room	temperature	(RT),	4,	and	–20°C.	The	
samples	stored	at	RT	and	4°C	were	transferred	to	–20°C	after	24	h.	
On	days	4	and	7,	the	samples	were	stored	directly	at	–20°C
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1 month of fecal collection, all samples were collected in a cooling bag 
and	transported	on	dry	ice	to	the	laboratory.	All	samples	were	evalu‐
ated upon arrival to ensure that they had not thawed and were stored 
at	−80°C	until	further	analyses,	which	was	within	8	months.
2.3 | RNA extraction
One	hundred	milligrams	of	feces	was	homogenized	in	1000	µL	RNase‐
free	water	in	M	Tubes	(Milteny,	Bergisch	Gladbach,	Germany)	on	a	gen-
tleMACS Octo	Dissociator	(Milteny,	Bergisch	Gladbach,	Germany).	RNA	
was	extracted	with	 a	miRNeasy	kit	 (Qiagen,	Hilden,	Germany)	by	 the	
addition	of	200	µL	homogenate	to	1200	µL	QIAzol	buffer	following	the	
manufacturer's	protocol	without	DNase	treatment.	The	RNA	concentra‐
tion and the purity of each sample were measured on a NanoDrop1000 
Spectrophotometer	(Thermo	Scientific,	Hvidovre,	Denmark).
2.4 | cDNA synthesis
Three	 cDNA	 replicates	 for	 each	 sample	 were	 made	 using	 100	 ng	
of	 total	 RNA	 for	 each	 synthesis	 according	 to	Balcells	 et	 al.9 Briefly, 
1	 µL	 10×	 Poly(A)	 Polymerase	 buffer	 (New	 England	 Biolabs,	
Massachusetts,	 USA),	 0.1	 mmol/L	 ATP,	 1	 µmol/L	 RT‐primer	
(5′‐CAGGTCCACTTTTTTTTTTTTTTTVN;	V	 =	A,	 C,	 or	 G;	 N	 =	A,	 C,	
G	 or	 T),	 0.1	 µmol/L	 deoxyadenosine	 triphosphate,	 0.1	 µmol/L	 de‐
oxycytidine	 triphosphate,	 0.1	 µmol/L	 deoxyguanosine	 triphosphate,	
0.1	 µmol/L	 deoxythymidine	 triphosphate,	 100	 units	MuLV	 Reverse	
Transcriptase	 (New	England	Biolabs),	 and	1	unit	Poly(A)	Polymerase	
(New	England	Biolabs)	were	mixed	with	 the	RNA	 in	 a	 final	 reaction	
volume	of	10	µL.	Negative	controls	were	made	by	exclusion	of	Poly(A)	
Polymerase.	cDNA	samples	were	diluted	eightfold	before	proceeding	
with qPCR.9
2.5 | Selection of miRNA candidates
Seventeen	 miRNAs	 (miR‐1224,	 miR‐155,	 miR‐194,	 miR‐26b,	
miR‐200a‐3p, let‐7g, miR‐192, miR‐141‐3p, miR‐574, let‐7a, 
miR‐29b‐3p, let‐7b, miR‐378, miR‐200b‐3p, miR‐23a‐3p, miR‐15a, 
and miR‐200c‐3p), previously found to be among the 50 most ex‐
pressed	 miRNAs	 in	 both	 human	 and	 mouse	 feces,	 were	 tested.10 
Furthermore,	miR‐16,	miR‐20a,	miR‐21,	miR‐26a,	and	miR‐92a	were	
included	based	on	human	fecal	miRNA	studies	that	were	known	to	be	
expressed in feces.7	Specific	miRNA	primers	were	designed	for	each	
of	the	22	miRNAs	using	the	miRSpecific	software11 as previously de‐
scribed (see Table 1).9,12
TA B L E  1  The	microRNAs	examined	in	this	study
Assay Forward primer Reverse primer
miR‐15a 5′‐GCAGTAGCAGCACATAATGG‐3′ 5′‐CCAGTTTTTTTTTTTTTTTACAAACCA‐3′
miR‐16 5′‐CAGTAGCAGCACGTAAATATTG‐3′ 5′‐CAGTTTTTTTTTTTTTTTCGCCAA‐3′
miR‐21 5′‐GCAGTAGCTTATCAGACTGATG‐3′ 5′‐GGTCCAGTTTTTTTTTTTTTTTCAAC‐3′
miR‐26a 5′‐GCAGTTCAAGTAATCCAGGATAG‐3′ 5′‐GTCCAGTTTTTTTTTTTTTTTAGCCT‐3′
miR‐26b 5′‐CGCAGTTCAAGTAATTCAGGA‐3′ 5′‐GGTCCAGTTTTTTTTTTTTTTTACCT‐3′
miR‐192 5′‐CAGCTGACCTATGAATTGACA‐3′ 5′‐CCAGTTTTTTTTTTTTTTTGGCTGT‐3′
miR‐200a‐3p 5′‐CAGTAACACTGTCTGGTAACG‐3′ 5′‐GGTCCAGTTTTTTTTTTTTTTTACATC‐3′
miR‐200c‐3p 5′‐AGTAATACTGCCGGGTAATG‐3′ 5′‐GTCCAGTTTTTTTTTTTTTTTCCATC‐3′
let7a‐5p 5′‐GCAGTGAGGTAGTAGGTTGT‐3′ 5′‐GGTCCAGTTTTTTTTTTTTTTAACTATAC‐3′
let7b‐5p 5′‐GTGAGGTAGTAGGTTGTGTG‐3′ 5′‐GGTCCAGTTTTTTTTTTTTTTTAACCA‐3′
miR‐141‐3p 5′‐GCAGTAACACTGTCTGG	TAAAG	3′ 5′‐GGTCCAGTTTTTTTTTTTTTTTCCAT‐3′
miR‐1224‐5p 5′‐GGTGAGGACTCGGGAG‐3′ 5′‐GGTCCAGTTTTTTTTTTTTTTTCCA‐3′
miR‐155 5′‐CGCAGTTAATGCTAATTGTG‐3′ 5′‐CAGTTTTTTTTTTTTTTTCCCCTATC‐3′
miR‐194 5′‐AGTGTAACAGCGACTCCA‐3′ 5′‐GTCCAGTTTTTTTTTTTTTTTCCAC‐3′
let‐7g 5′‐CGCAGTGAGGTAGTAGTTG‐3′ 5′‐CAGGTCCAGTTTTTTTTTTTTTTTAAC‐3′
miR‐29b‐3p 5′‐CATCTTTGTATCTAGCACCATTTGAAAT‐3′ 5′‐GGTCCAGTTTTTTTTTTTTTTTAACACT‐3′
miR‐378‐3p 5′‐AGACTGGACTTGGAGTCAG‐3′ 5′‐CAGTTTTTTTTTTTTTTTGCCTTCTG‐3′
miR‐574 5′‐TGAGTGTGTGTGTGTGAGT‐3′ 5′‐CAGGTCCAGTTTTTTTTTTTTTTTACA‐3′
miR‐194 5′‐AGTGTAACAGCGACTCCA‐3′ 5′‐GTCCAGTTTTTTTTTTTTTTTCCAC‐3′
miR‐200b‐3p 5′‐ACAGTAATACTGCCTGGTAATG‐3′ 5′‐GGTCCAGTTTTTTTTTTTTTTTCATC‐3′
miR‐23a‐3p 5′‐AUCACAUUGCCAGGGAUUUCCA‐3′ 5′‐CGTCCAGTTTTTTTTTTTTTTTGGAA‐3′
miR‐20a 5′‐CAGTAGCAGCACGTAAATATTG‐3′ 5′‐GTCCAGTTTTTTTTTTTTTTTCTACCT‐3′
miR‐92a 5′‐AGGTGTGTATAAAGTATTGCACTTGTCC‐3′ 5′‐CAGGTCCAGTTTTTTTTTTTTTTTACAG‐3′
Forward	and	reverse	primers	were	used.
Abbreviation:	miR,	microRNA.
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2.6 | Quantitative real‐time PCR
Quantitative	 real‐time	 PCR	 (qPCR)	was	 performed	 in	 an	M×3005	
Pro	qPCR	system	(Stratagene,	California,	USA)	using	the	associated	
software.	Quantifast	SYBRGreen	Master	Mix	(Qiagen)	was	used	with	
PCR	cycling	conditions	of	5	minutes	at	95°C,	40	cycles	of	10	sec‐
onds	 at	 95°C,	 and	 30	 seconds	 at	 60°C,	 followed	 by	 dissociation	
curve	analysis	of	1	minute	at	95°C,	30	seconds	at	55°C,	and	1	min‐
ute	at	95°C.	To	calculate	the	PCR	efficiency	for	each	assay,	standard	
curves	from	a	five‐time	dilution	series	of	a	pool	of	all	cDNA	samples	
were performed.
The obtained cycle of quantitation (Cq) values were prepro‐
cessed	 using	Genex	Pro	 software	 (Multid,	Gothenburg,	 Sweden).	
Briefly, Cq values were calibrated between plates for each assay, 
and PCR efficiency corrected. Replicates differing above two cy‐
cles from the two other replicates were excluded from the anal‐
ysis.	 The	 data	 were	 normalized	 using	 the	 most	 stable	 miRNA	
(let‐7b)	 according	 to	NormFinder	 and	GeNorm13,14 software pro‐
grams.	Subsequently,	replicates	were	averaged	for	further	analysis	
and relative quantities were calculated with respect to the least 
expressed sample in each assay. The data were log2 transformed 
before proceeding to statistical analysis. The qPCR experiments, 
as	well	as	the	data	analysis,	were	all	compliant	with	the	Minimum	
Information for publication of quantitative real‐time PCR experi‐
ments	(MIQE)	guidelines.15
2.7 | Statistical analyses
Log2‐transformed	 relative	 quantities	 for	 each	miRNA	were	 analyzed	
using linear mixed models, and using day temperature as an unbalanced 
interaction term and cats as random effects. Pairwise comparisons be‐
tween	combinations	of	day	and	temperature	were	carried	out.	A	P‐value 
of	<0.05	was	 considered	 significant.	All	 statistical	 analyses	were	 car‐
ried out using r (R Core Team, 2017) with the extension packages lme4 
and	multcomp.	Figures	and	descriptive	statistics	were	analyzed	using	
GraphPad	Prism	7	(GraphPad	Software,	San	Diego,	CA).	Normality	was	
assessed	using	the	D'Agostino	&	Pearson	normality	test.	Normally	dis‐
tributed	values	were	reported	as	the	mean	±	standard	deviation	(SD).
3  | RESULTS
3.1 | Patient demographics
Sixteen	 healthy	 client‐owned	 cats	 were	 screened	 for	 inclusion.	
Seven	cats	were	excluded	for	the	following	reasons:	mild	leukope‐
nia, mild neutropenia, or other significant abnormalities on hemo‐
gram,	biochemistry	panel	or	urinalysis	 (n	=	2);	 intestinal	parasites	
(n	 =	 1),	 diagnosed	 with	 feline	 idiopathic	 cystitis	 (n	 =	 1),	 chronic	
kidney	disease	(n	=	1),	aortic	murmur	(n	=	1),	and	incomplete	fecal	
collection	 by	 the	 client	 (n	 =	 1).	A	 total	 of	 nine	 healthy	 cats	were	
included in the study (see Table 2). The mean age was 60 months 
(SD:	38.5	months).	There	were	six	neutered	males	and	three	spayed	
females. The breeds included in the study were domestic shorthair 
(n	=	3),	Birma	(n	=	2),	and	an	n	=	1	of	each	of	the	following:	ragdoll,	
British	 shorthair,	 and	Bengal	 cats.	All	 cats	were	 fed	commercially	
available wet and/or dry cat food and diets were not changed dur‐
ing the study period.
3.2 | miRNA detection
We	 successfully	 isolated	 fecal	 miRNA	 from	 healthy	 cats	 using	 the	
miRNeasy kit (Qiagen). The miRNeasy kit produced an average of 
338	±	179	ng/µL	of	total	RNA	per	100	mg	of	feces.	The	averages	of	the	
purity ratios were for 260/280, 1.93 ± 0.1, and for 260/230, 1.33 ± 0.36, 
which indicated that there was very little protein contamination and 
some chemical contamination remaining in some of the samples.
All	qPCR	data	were	manually	curated,	and	 the	data	 that	did	not	
compile	with	standard	requirements	suggested	by	MIQE	guidelines15 
were excluded.
Primers	targeting	10	of	the	22	miRNAs	(miR15a,	miR16,	miR21,	
miR26a, miR26b, mir192, miR200a‐3p, miR200c‐3p, let7a, and 
let7b) resulted in mono‐peaked melting curves and a PCR efficiency 
between 80% and 110%, and were, therefore, included for further 
analyses.	 The	 remaining	 12	 miRNAs	 did	 not	 show	 mono‐peaked	
melting	curves	and	were	not	analyzed	further.
3.3 | Storage conditions at RT vs 4°C vs −20°C
No significant differences in the expression profiles of any of the 
miRNAs	were	seen	when	the	samples	were	stored	for	1	day	at	RT,	
4°C,	or	–20°C	(please	see	supporting	information	for	graphical	de‐
piction;	Figure	S1).	One	cat	had	no	data	points	for	any	of	the	three	
cDNA	replicates	 for	six	of	 the	miRNAs	 (miR‐15a,	miR‐16,	miR‐26a,	
miR‐26b, miR‐200a, and let‐7a), and for miR‐192 and let‐7b, the Cq 
was above 34 cycles and hence below the lower limit of quantitation 
in one or more of the triplicates from the feces stored at RT from 
day 1. The RT data from this cat was excluded from further analyses.
3.4 | miRNA expression over time
Only	one	miRNA	out	of	 nine	 analyzed,	 namely	miR26a,	 showed	a	
significant slight increase in expression (60% increase) between the 
TA B L E  2   Patient demographics of all healthy cats in this study
Cat ID Age (mo) Sex Breed
Cat 1 35 MN British shorthair
Cat 2 49 FS DSH
Cat 3 121 MN Birman
Cat 4 121 FS Birman
Cat 5 59 MN Ragdoll
Cat 6 14 MN DSH
Cat 7 47 MN Bengal
Cat 8 70 FS Bengal
Cat 9 24 MN DSH
Abbreviations:	DSH,	domestic	shorthair;	FS,	female	spayed;	MN,	male	
neutered.
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frozen	samples	from	the	collection	at	days	1	and	7	(P	=	0.0081;	the	
fold	change	=	1.59	with	a	95%	confidence	interval	of	1.13,	2.26)	as	
illustrated	in	Figure	2.	There	was	no	significant	difference	in	the	ex‐
pression	profiles	of	any	of	the	other	miRNAs	when	the	samples	from	
days	1,	4,	and	7	and	stored	at	–20°C	were	compared	(Please	see	sup‐
porting	information	for	graphical	depiction,	Figure	S2).
4  | DISCUSSION
This	study	is	the	first	to	identify	fecal	miRNAs	in	cats.	Some	of	these	
miRNAs	have	been	previously	isolated	in	blood	or	tissue	from	cats	
or dogs,8,16,17 while others have been implicated in tumorigenesis 
in humans and mice,18‐20 which makes them interesting targets for 
future analyses in cats with GI cancer.
Naturally evacuated feces are easily obtained by cat owners with 
indoor cats, but fecal collection still poses some practical challenges. 
Fecal	consistency	varies	between	bowel	movements	in	cats,	and	the	
presence and amount of fur could influence the assay results. Even 
though we did not use it in the present study, the ratios from the 
spectrophotometric	measurements	could	be	used	to	correlate	RNA	
purity with fecal consistency.
Three	 cDNA	 replicates	 from	each	RNA	sample	were	 analyzed,	
which improved the robustness of the results. Currently, there is a 
lack	of	 standardization	 in	 the	normalization	of	miRNA	qPCR	data,	
which	could	affect	final	data	analyses.	In	this	study,	we	normalized	
to	the	let‐7b	miRNA,	which	was	found	to	be	the	most	stable	of	the	
analyzed	miRNAs	using	two	gold‐standard	programs	of	normaliza‐
tion.13,14	According	 to	our	experience,	 it	 is	 strongly	 recommended	
that each time a new tissue or treatment/condition is investigated, a 
new panel of reference genes are assessed.
No	statistically	significant	difference	between	miRNA	expression	
in	samples	stored	for	24	hours	at	RT,	24	hours	at	4°C,	or	directly	at	
−20°C	were	identified.	These	results	are	in	contrast	to	prior	findings	
in feces from healthy dogs, where a significant difference was found 
in	cfa‐miR‐16	and	cfa‐miR‐21	stored	at	RT	and	−20°C,	respectively.8 
A	sample	 (RT)	from	one	cat	was	excluded	because	8/10	data	points	
were missing or Cq values were below the lower limit of quantitation. 
This	 sample	 had	 the	 lowest	 concentration	 of	 total	 RNA	 and	 lowest	
260/230	ratio	of	all	samples	indicating	problems	in	the	RNA	extraction	
procedure, which probably explains the poor qPCR results.
To the authors' knowledge, a systematic evaluation of stability 
from	human	 feces	has	not	been	performed.	However,	 it	 has	been	
suggested	that	miRNAs	are	“relatively	well‐preserved”	in	feces	from	
healthy human controls and patients with CRC, who performed 
in‐home fecal collections and transported the sample at RT to the 
laboratory, although the timeframe was not further specified in this 
study.21	In	this	feline	data,	miRNA	expression	levels	of	nine	miRNAs	
showed no significant differences between the three tested storage 
conditions	 indicating	 that	miRNAs	were	 clearly	more	 stable	 com‐
pared	with	those	of	mRNAs.22
Nevertheless,	for	long‐term	storage	or	analyses	of	other	miRNAs	
not	investigated	in	this	study,	we	recommend	freezing	the	samples	
as	soon	as	possible	at	−20	or	−80°C	to	ensure	stable	preservation.	
In	general,	storing	fecal	samples	for	miRNA	expression	studies	iden‐
tically to ensure minimal preanalytical variation would be beneficial.
Fecal	miRNA	expression	was	stable	 in	 the	healthy	cats	 for	eight	
out	 of	 the	 nine	miRNAs	 analyzed	 on	 the	 3	 days	 tested	 (days	 1,	 4,	
and	7).	MiRNA‐26a	 showed	significantly	 increased	 levels	 (60%,	 fold	
change	=	1.59)	between	days	1	and	7,	which	could	be	explained	by	
different fecal content compositions on day 7 compared with the rest 
of the samples for this cat, or it could indicate a real biologic increase in 
miR‐26a expression due to unknown physiologic reasons. Differences 
in dietary content would not explain these changes as each cat was fed 
the	same	diet	during	the	study	period.	This	miRNA	was	not	different	
in any of the other comparisons between samples stored at different 
temperatures,	frozen	samples	stored	at	days	1	and	4,	or	days	4	and	7.	
The miR‐26 family including miR‐26a and miR‐26b have been shown 
to be both tumor suppressors and to have oncogenic properties in dif‐
ferent cancer types. Interestingly, healthy canine plasma and serum 
miR‐26a expression were significantly decreased after an increase in 
storage temperatures,17 which illustrates that the carrier matrix plays a 
vital	role	in	miRNA	preservation.	In	light	of	these	results,	we	speculate	
that	miR‐26a	levels	are	more	variable	than	other	miRNAs.	And,	regard‐
ing	the	other	miRNAs,	it	appears	that	a	single	fecal	sample	is	sufficient	
to	assess	miRNA	expression	patterns	in	healthy	cats.	Since	no	studies	
have	been	performed	in	sick	cats,	it	is	unknown	if	miRNA	stability	will	
change or vary over time in these patients.
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